11th International AIDS Conference


Vancouver, British Columbia — July 7-12, 1996

Print this Article


Clinical trial of Buxux Sempervirens L. Preparation (SPV 30) in asymptomatic HIV infected patients.

Int Conf AIDS 1996 Jul 7-12; 11:30 (abstract no. LB.B.6040)
Vandermander J, Durant J, Chantre P, Dellamonica P; Arkopharma, Carros, France. Fax: 33.93.29.11.62.

OBJECTIVE: To assess the efficacy and safety of SPV 30 (a boxwood preparation listed in the Pharmacopea) in asymptomatic patients (group II-III, CDC 1987) with CD4+ cell count between 250 and 500/mm3 at day 1.

METHODS: 150 asymptomatic patients have been followed for 12 to 18 months during a phase II-III, multicenter, placebo controlled trial comparing 2 doses of SPV 30. Clinical safety (all adverse events occurring and withdrawals), as well as change in CD4 cell counts/mm3 and charge in viral load were investigated.

RESULTS: Statistics will be finalized by the end of June and presented during the conference.

960707
LBB6040

Copyright © 1996 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.